Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
45
CMPX Quote, Financials, Valuation and Earnings
Last price:
$5.26
Seasonality move
:
2.61%
Day range:
$5.09 - $5.39
52-week range:
$1.33 - $5.86
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.36x
Volume:
1.6M
Avg. volume:
2M
1-year change:
211.52%
Market cap:
$914.2M
Revenue:
$850K
EPS (TTM):
-$0.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
-- | -$0.13 | -100% | -16.28% | $12.62 |
|
ACHC
Acadia Healthcare Co., Inc.
|
$846.4M | $0.66 | 3.57% | 15.63% | $21.57 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-- | -$0.16 | -- | -47.25% | $9.67 |
|
PRAX
Praxis Precision Medicines, Inc.
|
$59.4K | -$3.49 | -96.8% | -6.23% | $374.20 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -1.16% | 33.42% | $781.13 |
|
STOK
Stoke Therapeutics, Inc.
|
$6.2M | -$0.57 | -77.5% | -289.69% | $32.38 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
$5.14 | $12.62 | $914.2M | -- | $0.00 | 0% | -- |
|
ACHC
Acadia Healthcare Co., Inc.
|
$14.01 | $21.57 | $1.3B | 11.89x | $0.00 | 0% | 0.39x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$4.79 | $9.67 | $288.2M | -- | $0.00 | 0% | -- |
|
PRAX
Praxis Precision Medicines, Inc.
|
$258.13 | $374.20 | $6.5B | -- | $0.00 | 0% | 730.57x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$692.58 | $781.13 | $72.8B | 16.58x | $0.88 | 0.51% | 5.36x |
|
STOK
Stoke Therapeutics, Inc.
|
$30.47 | $32.38 | $1.7B | 46.17x | $0.00 | 0% | 8.65x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
4.5% | 5.180 | 1.59% | 17.72x |
|
ACHC
Acadia Healthcare Co., Inc.
|
43.75% | 1.294 | 100.77% | 1.06x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 1.936 | 4.95% | 2.64x |
|
PRAX
Praxis Precision Medicines, Inc.
|
0.13% | 4.602 | 0.04% | 5.05x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
|
STOK
Stoke Therapeutics, Inc.
|
1.53% | 2.663 | 0.37% | 6.17x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
-$371K | -$15.8M | -45.93% | -48.62% | -1770% | -$10.9M |
|
ACHC
Acadia Healthcare Co., Inc.
|
$171M | $119.5M | 2.18% | 3.71% | 14.04% | -$63M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
PRAX
Praxis Precision Medicines, Inc.
|
-$19K | -$78.4M | -67.57% | -67.75% | -856.97% | -$64.7M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
STOK
Stoke Therapeutics, Inc.
|
$9.6M | -$43.1M | 13.73% | 13.95% | -405.3% | -$30.5M |
Compass Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CMPX or ACHC?
Acadia Healthcare Co., Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of 4.5%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Acadia Healthcare Co., Inc.'s return on equity of 3.71%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.08 $219.5M ACHCAcadia Healthcare Co., Inc.20.08% $0.40 $5.7B -
What do Analysts Say About CMPX or ACHC?
Compass Therapeutics, Inc. has a consensus price target of $12.62, signalling upside risk potential of 145.44%. On the other hand Acadia Healthcare Co., Inc. has an analysts' consensus of $21.57 which suggests that it could grow by 53.97%. Given that Compass Therapeutics, Inc. has higher upside potential than Acadia Healthcare Co., Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Acadia Healthcare Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.11 0 0 ACHCAcadia Healthcare Co., Inc.6 5 0 -
Is CMPX or ACHC More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Acadia Healthcare Co., Inc. has a beta of 0.906, suggesting its less volatile than the S&P 500 by 9.448%.
-
Which is a Better Dividend Stock CMPX or ACHC?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acadia Healthcare Co., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Acadia Healthcare Co., Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or ACHC?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Acadia Healthcare Co., Inc. quarterly revenues of $851.6M. Compass Therapeutics, Inc.'s net income of -$14.3M is lower than Acadia Healthcare Co., Inc.'s net income of $38.3M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Acadia Healthcare Co., Inc.'s PE ratio is 11.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 0.39x for Acadia Healthcare Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$14.3M ACHCAcadia Healthcare Co., Inc.0.39x 11.89x $851.6M $38.3M
-
Which has Higher Returns CMPX or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of --. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.08 $219.5M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About CMPX or ALDX?
Compass Therapeutics, Inc. has a consensus price target of $12.62, signalling upside risk potential of 145.44%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 101.81%. Given that Compass Therapeutics, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.11 0 0 ALDXAldeyra Therapeutics, Inc.5 0 0 -
Is CMPX or ALDX More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.
-
Which is a Better Dividend Stock CMPX or ALDX?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or ALDX?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Aldeyra Therapeutics, Inc. quarterly revenues of --. Compass Therapeutics, Inc.'s net income of -$14.3M is lower than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$14.3M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns CMPX or PRAX?
Praxis Precision Medicines, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of -786.27%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Praxis Precision Medicines, Inc.'s return on equity of -67.75%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.08 $219.5M PRAXPraxis Precision Medicines, Inc.-- -$3.36 $343.9M -
What do Analysts Say About CMPX or PRAX?
Compass Therapeutics, Inc. has a consensus price target of $12.62, signalling upside risk potential of 145.44%. On the other hand Praxis Precision Medicines, Inc. has an analysts' consensus of $374.20 which suggests that it could grow by 44.97%. Given that Compass Therapeutics, Inc. has higher upside potential than Praxis Precision Medicines, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Praxis Precision Medicines, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.11 0 0 PRAXPraxis Precision Medicines, Inc.12 0 1 -
Is CMPX or PRAX More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Praxis Precision Medicines, Inc. has a beta of 2.946, suggesting its more volatile than the S&P 500 by 194.607%.
-
Which is a Better Dividend Stock CMPX or PRAX?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Praxis Precision Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Praxis Precision Medicines, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or PRAX?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Praxis Precision Medicines, Inc. quarterly revenues of --. Compass Therapeutics, Inc.'s net income of -$14.3M is higher than Praxis Precision Medicines, Inc.'s net income of -$73.9M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Praxis Precision Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 730.57x for Praxis Precision Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$14.3M PRAXPraxis Precision Medicines, Inc.730.57x -- -- -$73.9M
-
Which has Higher Returns CMPX or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of 38.89%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.08 $219.5M REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About CMPX or REGN?
Compass Therapeutics, Inc. has a consensus price target of $12.62, signalling upside risk potential of 145.44%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 12.79%. Given that Compass Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.11 0 0 REGNRegeneron Pharmaceuticals, Inc.16 8 0 -
Is CMPX or REGN More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock CMPX or REGN?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.51% to investors and pays a quarterly dividend of $0.88 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or REGN?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Compass Therapeutics, Inc.'s net income of -$14.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 16.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 5.36x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$14.3M REGNRegeneron Pharmaceuticals, Inc.5.36x 16.58x $3.8B $1.5B
-
Which has Higher Returns CMPX or STOK?
Stoke Therapeutics, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of -360.68%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.08 $219.5M STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M -
What do Analysts Say About CMPX or STOK?
Compass Therapeutics, Inc. has a consensus price target of $12.62, signalling upside risk potential of 145.44%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $32.38 which suggests that it could grow by 6.25%. Given that Compass Therapeutics, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Stoke Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.11 0 0 STOKStoke Therapeutics, Inc.9 0 0 -
Is CMPX or STOK More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.807%.
-
Which is a Better Dividend Stock CMPX or STOK?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or STOK?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Compass Therapeutics, Inc.'s net income of -$14.3M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Stoke Therapeutics, Inc.'s PE ratio is 46.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 8.65x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$14.3M STOKStoke Therapeutics, Inc.8.65x 46.17x $10.6M -$38.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
Sell
6
ODC alert for Dec 10
Oil-Dri Corp. of America [ODC] is up 3.07% over the past day.
Buy
84
PAAS alert for Dec 10
Pan American Silver Corp. [PAAS] is up 0.5% over the past day.
